Skip to main content
Erschienen in: International Journal of Hematology 6/2016

15.03.2016 | Original Article

Miscarriage and recurrent miscarriage in patients with congenital factor V deficiency: a report of six cases in Iran

verfasst von: Majid Naderi, Shadi Tabibian, Morteza Shamsizadeh, Akbar Dorgalaleh

Erschienen in: International Journal of Hematology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Miscarriage and recurrent miscarriage have not been reported in women with congenital factor V (FV) deficiency. Here we describe cases of both miscarriage and recurrent miscarriage in women with congenital FV deficiency (FVD). We investigated six women with FVD from the southeast of Iran who had experienced miscarriage and recurrent miscarriage. Consequent diagnosis was made by routine coagulation tests as well as FV activity and antigen assays. To evaluate the presence of an inhibitor, a mixing study via prothrombin time (PT) assay was performed. All patients were investigated, and found to be negative for antiphospholipid syndrome. Demographic data and clinical presentations were obtained by standard questionnaire. The factor assays determined that all six women were suffering from moderate FVD. One had experienced eight miscarriages, while the others experienced two (two patients), three, and four episodes. Only one patient had a single miscarriage. Three of the women experienced successful delivery without medical intervention. Miscarriage and recurrent miscarriage should be considered as possible presentations of FVD to prevent its life-threatening consequences.
Literatur
1.
2.
Zurück zum Zitat Naderi M, Tabibian S, Hosseini MS, Alizadeh S, Hosseini S, Shamsizadeh M, et al. Congenital combined deficiency of coagulation factors: a study of seven patients. Blood Coagul Fibrinolysis. 2015;26(1):59–62.CrossRefPubMed Naderi M, Tabibian S, Hosseini MS, Alizadeh S, Hosseini S, Shamsizadeh M, et al. Congenital combined deficiency of coagulation factors: a study of seven patients. Blood Coagul Fibrinolysis. 2015;26(1):59–62.CrossRefPubMed
3.
Zurück zum Zitat Naderi M, Tabibian S, Hosseini MS, Alizadeh S, Hosseini S, Karami H, et al. Rare bleeding disorders: a narrative review of epidemiology, molecular and clinical presentations, diagnosis and treatment. J Pediatr Rev. 2014;2(2):31–46. Naderi M, Tabibian S, Hosseini MS, Alizadeh S, Hosseini S, Karami H, et al. Rare bleeding disorders: a narrative review of epidemiology, molecular and clinical presentations, diagnosis and treatment. J Pediatr Rev. 2014;2(2):31–46.
4.
Zurück zum Zitat Naderi M, Tabibian S, Dorgalaleh A, Kashani Kahtib Z, Alizadeh S. Public health problems related to factor V deficiency in southeast of Iran. Med J Islam Repub Iran. 2014;28(1):171–3. Naderi M, Tabibian S, Dorgalaleh A, Kashani Kahtib Z, Alizadeh S. Public health problems related to factor V deficiency in southeast of Iran. Med J Islam Repub Iran. 2014;28(1):171–3.
5.
Zurück zum Zitat Naderi M, Tabibian S, Alizadeh S, Hosseini S, Zaker F, Bamedi T, et al. Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders. Acta Haematol. 2014;133(2):148–54.CrossRefPubMed Naderi M, Tabibian S, Alizadeh S, Hosseini S, Zaker F, Bamedi T, et al. Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders. Acta Haematol. 2014;133(2):148–54.CrossRefPubMed
6.
Zurück zum Zitat SanneVellinga ES, IngeVangenechten AG. Successful pregnancy in a patient with factor V deficiency: case report and review of the literature. Thromb Haemost. 2006;95:896–7. SanneVellinga ES, IngeVangenechten AG. Successful pregnancy in a patient with factor V deficiency: case report and review of the literature. Thromb Haemost. 2006;95:896–7.
7.
Zurück zum Zitat Girolami A, Scandellari R, Lombardi A, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia. 2005;11(1):26–30.CrossRefPubMed Girolami A, Scandellari R, Lombardi A, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia. 2005;11(1):26–30.CrossRefPubMed
8.
Zurück zum Zitat Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41(3):323–9.CrossRefPubMed Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41(3):323–9.CrossRefPubMed
9.
Zurück zum Zitat Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Hosseini MS, et al. Clinical manifestations and bleeding episodes among heterozygote individuals of factor XIII deficiency, a short term prospective study. Blood. 2014;124(21):2852. Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Hosseini MS, et al. Clinical manifestations and bleeding episodes among heterozygote individuals of factor XIII deficiency, a short term prospective study. Blood. 2014;124(21):2852.
10.
Zurück zum Zitat Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Shamsizadeh M, et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol. 2014;100(5):443–9.CrossRefPubMed Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Shamsizadeh M, et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol. 2014;100(5):443–9.CrossRefPubMed
11.
Zurück zum Zitat Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451–5.CrossRefPubMed Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451–5.CrossRefPubMed
12.
13.
Zurück zum Zitat O’Connell M, Eogan M, Murphy K, White B, Keane D, O’Donnell J. Solvent–detergent plasma as replacement therapy in a pregnant patient with factor V deficiency. J Matern-Fetal Neonatal Med. 2004;16(1):69–70.CrossRefPubMed O’Connell M, Eogan M, Murphy K, White B, Keane D, O’Donnell J. Solvent–detergent plasma as replacement therapy in a pregnant patient with factor V deficiency. J Matern-Fetal Neonatal Med. 2004;16(1):69–70.CrossRefPubMed
14.
Zurück zum Zitat Naderi M, Reykande SE, Dorgalaleh A, Alizadeh S, Tabibian S, Einollahi N, et al. Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran. Blood Coagul Fibrinolysis. 2016;27(1):97–100.CrossRefPubMed Naderi M, Reykande SE, Dorgalaleh A, Alizadeh S, Tabibian S, Einollahi N, et al. Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran. Blood Coagul Fibrinolysis. 2016;27(1):97–100.CrossRefPubMed
Metadaten
Titel
Miscarriage and recurrent miscarriage in patients with congenital factor V deficiency: a report of six cases in Iran
verfasst von
Majid Naderi
Shadi Tabibian
Morteza Shamsizadeh
Akbar Dorgalaleh
Publikationsdatum
15.03.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-1981-7

Weitere Artikel der Ausgabe 6/2016

International Journal of Hematology 6/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.